Moderna Inc. has announced the full approval from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, Spikevax, specifically for children aged 6 months through 11 years who are at increased risk for COVID-19 disease. This approval marks a significant step as the vaccine, previously available under Emergency Use Authorization for pediatric populations, can now be administered with full approval in this age group. Moderna's CEO, Stéphane Bancel, emphasized the importance of vaccination for protecting children, especially those with underlying health conditions. The company plans to have the updated Spikevax vaccine available in the U.S. for the 2025-2026 respiratory virus season.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。